Additional data tables for Aboriginal and Torres Strait Islander participants
Screening HPV test positivity for Aboriginal and Torres Strait Islander participants
Birth cohort | Oncogenic HPV | Oncogenic HPV | Oncogenic HPV |
|---|---|---|---|
Indigenous | 657 | 3,170 | 3,827 |
Non-Indigenous | 13,913 | 55,515 | 69,428 |
Not stated | 4,324 | 20,481 | 24,805 |
Total 25–74 | 18,894 | 79,166 | 98,060 |
Indigenous | 256 | 2,302 | 2,558 |
Non-Indigenous | 4,311 | 34,345 | 38,656 |
Not stated | 1,806 | 15,797 | 17,603 |
Total birth cohort offered HPV vaccination | 6,373 | 52,444 | 58,817 |
Indigenous | 404 | 928 | 1,332 |
Non-Indigenous | 9,695 | 21,831 | 31,526 |
Not stated | 2,580 | 5,392 | 7,972 |
Total birth cohort not offered HPV vaccination | 12,679 | 28,151 | 40,830 |
Note: Participants born after 30 June 1980 were considered to have been offered HPV vaccination as these participants were eligible for the school or catch-up program during 2007; Participants born on or before 30 June 1980 were considered to have not been offered HPV vaccination, as these participants were outside the eligible age for HPV vaccination.
Aboriginal and Torres Strait Islander women are respectfully referred to as Indigenous women in this table.
Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).
Age group | Oncogenic HPV | Oncogenic HPV | Oncogenic HPV |
|---|---|---|---|
Indigenous | 1.9 | 9.4 | 11.4 |
Non-Indigenous | 1.3 | 5.3 | 6.6 |
Not stated | 1.7 | 8.0 | 9.7 |
Total 25–74 | 1.4 | 5.9 | 7.3 |
Indigenous | 1.5 | 13.2 | 14.7 |
Non-Indigenous | 1.0 | 8.1 | 9.1 |
Not stated | 1.5 | 13.0 | 14.5 |
Total birth cohort offered HPV vaccination | 1.1 | 9.3 | 10.5 |
Indigenous | 2.4 | 5.6 | 8.0 |
Non-Indigenous | 1.5 | 3.4 | 5.0 |
Not stated | 1.8 | 3.9 | 5.7 |
Total birth cohort not offered HPV vaccination | 1.6 | 3.6 | 5.2 |
Notes: Participants born after 30 June 1980 were considered to have been offered HPV vaccination as these participants were eligible for the school or catch-up program during 2007; Participants born on or before 30 June 1980 were considered to have not been offered HPV vaccination, as these participants were outside the eligible age for HPV vaccination.
Aboriginal and Torres Strait Islander participants are respectfully referred to as Indigenous participants in this table.
Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).
Year | Birth cohort | Oncogenic HPV | Oncogenic HPV | Oncogenic HPV |
|---|---|---|---|---|
2018 | 25–74 | 992 | 3,384 | 4,376 |
2019 | 25–74 | 925 | 3,268 | 4,193 |
2020 | 25–74 | 511 | 1,965 | 2,476 |
2021 | 25–74 | 356 | 1,474 | 1,830 |
2022 | 25–74 | 322 | 1,503 | 1,825 |
2023 | 25–74 | 617 | 2,671 | 3,288 |
2024 | 25–74 | 657 | 3,170 | 3,827 |
2018 | vaccine offered | 396 | 2,570 | 2,966 |
2019 | vaccine offered | 359 | 2,404 | 2,763 |
2020 | vaccine offered | 245 | 1,546 | 1,791 |
2021 | vaccine offered | 176 | 1,188 | 1,364 |
2022 | vaccine offered | 150 | 1,220 | 1,370 |
2023 | vaccine offered | 221 | 1,963 | 2,184 |
2024 | vaccine offered | 256 | 2,302 | 2,558 |
2018 | vaccine not offered | 616 | 1,250 | 1,866 |
2019 | vaccine not offered | 586 | 1,138 | 1,724 |
2020 | vaccine not offered | 274 | 556 | 830 |
2021 | vaccine not offered | 186 | 365 | 551 |
2022 | vaccine not offered | 177 | 345 | 522 |
2023 | vaccine not offered | 398 | 771 | 1,169 |
2024 | vaccine not offered | 404 | 928 | 1,332 |
Note: Participants born after 30 June 1980 were considered to have been offered HPV vaccination as these participants were eligible for the school or catch-up program during 2007; Participants born on or before 30 June 1980 were considered to have not been offered HPV vaccination, as these participants were outside the eligible age for HPV vaccination.
Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).
Year | Birth cohort | Oncogenic HPV | Oncogenic HPV | Oncogenic HPV |
|---|---|---|---|---|
2018 | 25–74 | 2.7 | 9.2 | 11.9 |
2019 | 25–74 | 2.6 | 9.2 | 11.9 |
2020 | 25–74 | 2.8 | 10.7 | 13.4 |
2021 | 25–74 | 2.6 | 10.9 | 13.6 |
2022 | 25–74 | 2.4 | 11.4 | 13.8 |
2023 | 25–74 | 2.1 | 9.3 | 11.4 |
2024 | 25–74 | 1.9 | 9.4 | 11.4 |
2018 | vaccine offered | 2.4 | 15.6 | 18.0 |
2019 | vaccine offered | 2.3 | 15.2 | 17.5 |
2020 | vaccine offered | 2.4 | 15.3 | 17.8 |
2021 | vaccine offered | 2.2 | 14.9 | 17.1 |
2022 | vaccine offered | 1.9 | 15.1 | 17.0 |
2023 | vaccine offered | 1.6 | 13.8 | 15.3 |
2024 | vaccine offered | 1.5 | 13.2 | 14.7 |
2018 | vaccine not offered | 2.8 | 5.7 | 8.5 |
2019 | vaccine not offered | 2.9 | 5.6 | 8.4 |
2020 | vaccine not offered | 3.1 | 6.3 | 9.4 |
2021 | vaccine not offered | 3.2 | 6.3 | 9.5 |
2022 | vaccine not offered | 3.3 | 6.4 | 9.7 |
2023 | vaccine not offered | 2.7 | 5.2 | 7.9 |
2024 | vaccine not offered | 2.4 | 5.6 | 8.0 |
Note: Participants born after 30 June 1980 were considered to have been offered HPV vaccination as these participants were eligible for the school or catch-up program during 2007; Participants born on or before 30 June 1980 were considered to have not been offered HPV vaccination, as these participants were outside the eligible age for HPV vaccination.
Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).
Colposcopy rate for Aboriginal and Torres Strait Islander participants
Indigenous status | Number of colposcopies | Colposcopy rate (%) |
|---|---|---|
Indigenous | 482 | 38.3 |
Non-Indigenous | 14,713 | 48.4 |
Not stated | 4,042 | 43.5 |
Australia | 19,237 | 47.0 |
Notes: Colposcopy rate is the number of participants who have a colposcopy within 3 months as a per cent of the number of participants who are at higher risk of a significant cervical abnormality.
Aboriginal and Torres Strait Islander participants are respectfully referred to as Indigenous participants in this table.
Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).
Indigenous status | Major cities | Inner regional | Outer regional | Remote | Very remote |
|---|---|---|---|---|---|
Indigenous | 41.2 | 41.5 | 39.9 | 21.5 | 25.1 |
Non-Indigenous | 49.0 | 48.0 | 45.2 | 41.7 | 25.4 |
Not stated | 43.3 | 44.4 | 44.3 | 40.9 | 49.5 |
Australia | 47.5 | 46.9 | 44.6 | 38.5 | 27.9 |
Notes:
- Colposcopy rate is the number of participants who have a colposcopy within 3 months as a per cent of the number of participants who are at higher risk of a significant cervical abnormality.
- Participants were allocated to a remoteness area using their SA2 at the time of their screen (or postcode where SA2 was not available) according to the Australian Statistical Geography Standard (ASGS) for 2021.
Aboriginal and Torres Strait Islander participants are respectfully referred to as Indigenous participants in this table.
Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).
High-grade cervical abnormality detection for Aboriginal and Torres Strait Islander participants
Indigenous status | Number participants with high-grade abnormality detected | Number participants screened | High-grade cervical abnormality detection | High-grade cervical abnormality detection |
|---|---|---|---|---|
Indigenous | 591 | 47,310 | 12.5 | 11.8 |
Non-Indigenous | 8,993 | 1,353,644 | 6.6 | 7.2 |
Not stated | 2,987 | 345,938 | 8.6 | 8.4 |
Australia | 12,571 | 1,746,892 | 7.2 | 7.5 |
Notes:
- Crude rate is the number of participants with a high-grade abnormality detected on histology per 1,000 participants screened.
- Age-standardised (AS) rate is the number of participants with a high-grade abnormality detected on histology per 1,000 participants screened, age-standardised to the Australian population as at 30 June 2001.
Aboriginal and Torres Strait Islander participants are respectfully referred to as Indigenous participants in this table.
Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).
Year | Number participants with high-grade abnormality detected | Number participants screened | High-grade cervical abnormality detection | High-grade cervical abnormality detection |
|---|---|---|---|---|
2018 | 576 | 46,178 | 12.5 | 11.0 |
2019 | 637 | 46,688 | 13.6 | 12.1 |
2020 | 664 | 30,950 | 21.5 | 18.7 |
2021 | 607 | 25,646 | 23.7 | 21.0 |
2022 | 505 | 25,354 | 19.9 | 17.4 |
2023 | 520 | 41,548 | 12.5 | 11.8 |
2024 | 591 | 47,310 | 12.5 | 11.8 |
Note: Crude rate is the number of participants with a high-grade abnormality detected on histology per 1,000 participants screened. Age-standardised (AS) rate is the number of participants with a high-grade abnormality detected on histology per 1,000 participants screened, age-standardised to the Australian population as at 30 June 2001.
Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).
Incidence of cervical cancer for Aboriginal and Torres Strait Islander women
Indigenous status | New cases | Crude rate | AS rate |
|---|---|---|---|
Indigenous | 194 | 19.1 | 19.9 |
Non-Indigenous | 3,425 | 9.8 | 10.1 |
Not stated | 232 | . . | . . |
Total | 3,851 | 10.7 | 11.0 |
Notes:
- Data shown are for New South Wales, Victoria, Queensland, Western Australia, the Australian Capital Territory, and the Northern Territory only; data from these jurisdictions were considered to have adequate levels of Indigenous identification in cancer registration data at the time this report was prepared.
- Some states and territories use an imputation method for determining cancers among Indigenous people, which may lead to differences between these data and those shown in jurisdictional cancer incidence reports.
- Crude rate is the number of new cases of cervical cancer per 100,000 females in the population. Age-standardised (AS) rate is the number of new cases of cervical cancer per 100,000 females in the population, age-standardised to the Australian population as at 30 June 2001.
Aboriginal and Torres Strait Islander women are respectfully referred to as Indigenous women in this table.
Source: AIHW Australian Cancer Database 2021.
Mortality from cervical cancer for Aboriginal and Torres Strait Islander women
Indigenous status | All Australian deaths | Deaths | Crude rate | AS rate |
|---|---|---|---|---|
Indigenous | 77 | 71 | 6.9 | 7.4 |
Non-Indigenous | 853 | 630 | 2.3 | 2.2 |
Not stated | 8 | 5 | . . | . . |
Total | 938 | 706 | 2.5 | 2.4 |
Notes
- Data shown for 'All Australian deaths' are for all states and territories combined; data shown for 'Deaths' are for New South Wales, Queensland, Western Australia, South Australia, and the Northern Territory only; data from these jurisdictions were considered to have adequate levels of Indigenous identification in cancer mortality data at the time this report was prepared. Caution should be used when interpreting data for 'All Australian deaths' as these include jurisdictions that do not have adequate levels of Indigenous identification.
- Deaths from 2019 to 2022 were derived by year of death; deaths in 2023 were derived by year of registration of death. Deaths registered in 2020 and earlier are based on the final version of cause-of-death data; deaths registered in 2021 are based on revised versions; and deaths registered in 2022 and 2023 are based on preliminary versions. Revised and preliminary versions are subject to further revision by the ABS.
- Crude rate is the number of deaths from cervical cancer in New South Wales, Queensland, Western Australia, South Australia, and the Northern Territory per 100,000 females in the population.
- Age-standardised (AS) rate is the number of deaths from cervical cancer in New South Wales, Queensland, Western Australia, South Australia, and the Northern Territory per 100,000 females in the population, age-standardised to the Australian population as at 30 June 2001.
Aboriginal and Torres Strait Islander women are respectfully referred to as Indigenous women in this table.
Source: AIHW National Mortality Database.
Box Indigenous people 3: Aboriginal and Torres Strait Islander women incidence and mortality populations and rates
To derive cervical cancer incidence and mortality rates for Aboriginal and Torres Strait Islander peoples, this report used Indigenous population estimates and projections based on the 2021 Census.
The final estimated resident Indigenous population as at 30 June 2021 was 25.2% higher than the estimated population as at 30 June 2016 (ABS 2023). The extent of the increase in the Indigenous population estimates between 2016 and 2021 means that any rates calculated with Indigenous population estimates based on the 2021 Census will be lower than those based on the 2016 Census and should not be compared with rates calculated using populations based on previous Censuses.
For further information, see Understanding change in counts of Aboriginal and Torres Strait Islander people and Guide to using historical estimates for comparative analysis and reporting.